The Patent Finder
BB

Biond Biologics Ltd.

First filing 2020
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Eight patents currently held, every record listed here

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Aug 2040. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Aug 2040
Next term end
6
Patent families

When these terms end

Each bar runs from grant to computed term end. 2022 to 2043.
US 11,236,162 Antibodies Against ILT2 Aug 12, 2040
US 12,071,479 Antibodies Against ILT2 and Use Thereof Aug 12, 2040
US 12,391,755 Methods of Use for Anti- ILT2 Antibodies Aug 12, 2040
US 12,139,534 Methods and Compositions for Decreasing Soluble Immune Receptor CD28 Feb 23, 2042
US 12,544,451 Intracellular Delivery Compositions Apr 20, 2042
US 12,612,459 Methods of Identifying Agents That Block MCD28 Cleavage by MMPS Mar 10, 2043
US 12,503,510 Small Shedding Blocking Agents Mar 17, 2043
US 12,589,163 Shedding Blocking Agents with Increased Stability Apr 18, 2043
202620302034203820422043
13 pending applications: term is not computable until grant.Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Fee deadlines

No maintenance fee falls due on this company's record before Nov 10, 2027.

Recent changes

What they patent

The 5 largest of its 6 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 8 of 8

PatentTitleStatusExpiresConfidence
US 11,236,162Antibodies Against ILT2
In force
 · High confidence
In forceHigh confidence
US 12,071,479Antibodies Against ILT2 and Use Thereof
In force
 · High confidence
In forceHigh confidence
US 12,391,755Methods of Use for Anti- ILT2 Antibodies
In force
 · High confidence
In forceHigh confidence
US 12,139,534Methods and Compositions for Decreasing Soluble Immune Receptor CD28
In force
 · High confidence
In forceHigh confidence
US 12,544,451Intracellular Delivery Compositions
In force
 · High confidence
In forceHigh confidence
US 12,612,459Methods of Identifying Agents That Block MCD28 Cleavage by MMPS
In force
 · High confidence
In forceHigh confidence
US 12,503,510Small Shedding Blocking Agents
In force
 · High confidence
In forceHigh confidence
US 12,589,163Shedding Blocking Agents with Increased Stability
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 8: 13 applications pending · 2 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited